136 related articles for article (PubMed ID: 37366040)
1. Improved concordance of challenging human epidermal growth factor receptor 2 dual in-situ hybridisation cases with the use of a digital image analysis algorithm in breast cancer.
Gough M; Liu C; Srinivasan B; Wilkinson L; Dunk L; Yang Y; Schreiber V; Tuffaha H; Kryza T; Hooper JD; Lakhani SR; Snell CE
Histopathology; 2023 Oct; 83(4):647-656. PubMed ID: 37366040
[TBL] [Abstract][Full Text] [Related]
2. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
3. Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.
Shanmugalingam A; Hitos K; Pathmanathan N; Edirimmane S; Hughes TM; Ngui NK
Breast Cancer Res Treat; 2023 Feb; 198(1):143-148. PubMed ID: 36604351
[TBL] [Abstract][Full Text] [Related]
4. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
5. Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry.
Helin HO; Tuominen VJ; Ylinen O; Helin HJ; Isola J
Virchows Arch; 2016 Feb; 468(2):191-8. PubMed ID: 26493985
[TBL] [Abstract][Full Text] [Related]
6. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
7. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
8. Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.
Sapino A; Maletta F; Verdun di Cantogno L; Macrì L; Botta C; Gugliotta P; Scalzo MS; Annaratone L; Balmativola D; Pietribiasi F; Bernardi P; Arisio R; Viberti L; Guzzetti S; Orlassino R; Ercolani C; Mottolese M; Viale G; Marchiò C
Oncologist; 2014 Nov; 19(11):1118-26. PubMed ID: 25323485
[TBL] [Abstract][Full Text] [Related]
9. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays.
Laurinaviciene A; Dasevicius D; Ostapenko V; Jarmalaite S; Lazutka J; Laurinavicius A
Diagn Pathol; 2011 Sep; 6():87. PubMed ID: 21943197
[TBL] [Abstract][Full Text] [Related]
10. Dual-color dual-hapten in situ hybridization (D-DISH) - Comparison with fluorescence in situ hybridization (FISH) for HER2/neu testing in breast cancer.
Gajaria PK; Tambe S; Pai T; Patil A; Desai SB; Shet TM
Indian J Pathol Microbiol; 2020; 63(2):194-199. PubMed ID: 32317514
[TBL] [Abstract][Full Text] [Related]
11. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
12. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
[TBL] [Abstract][Full Text] [Related]
13. The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization.
Farshid G; Dhatrak D; Gilhotra A; Koszyca B; Nolan J
Mod Pathol; 2020 Sep; 33(9):1783-1790. PubMed ID: 32366941
[TBL] [Abstract][Full Text] [Related]
14. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.
Dietel M; Ellis IO; Höfler H; Kreipe H; Moch H; Dankof A; Kölble K; Kristiansen G
Virchows Arch; 2007 Jul; 451(1):19-25. PubMed ID: 17562074
[TBL] [Abstract][Full Text] [Related]
15. Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study.
Baez-Navarro X; van Bockstal MR; Nawawi D; Broeckx G; Colpaert C; Doebar SC; Hogenes MCH; Koop E; Lambein K; Peeters DJE; Sinke RHJA; Bastiaan van Brakel J; van der Starre-Gaal J; van der Vegt B; van de Vijver K; Vreuls CPH; Vreuls W; Westenend PJ; van Deurzen CHM
Mod Pathol; 2023 Jan; 36(1):100009. PubMed ID: 36788064
[TBL] [Abstract][Full Text] [Related]
16. Validation of Dual-Color Dual In Situ Hybridization for HER2/neu Gene in Breast Cancer.
Rathi A; Sahay A; Shet TM; Patil A; Desai SB
Arch Pathol Lab Med; 2024 Apr; 148(4):453-460. PubMed ID: 37490416
[TBL] [Abstract][Full Text] [Related]
17. Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.
Ercolani C; Marchiò C; Di Benedetto A; Fabi A; Perracchio L; Vici P; Sperati F; Buglioni S; Arena V; Pescarmona E; Sapino A; Terrenato I; Mottolese M
J Exp Clin Cancer Res; 2017 Oct; 36(1):143. PubMed ID: 29029640
[TBL] [Abstract][Full Text] [Related]
18. Practical application of non-contact alternating current electric field mixing for reagent-saving in situ hybridisation of HER2.
Kurihara N; Imai K; Nanjo H; Nakamura R; Wakamatsu Y; Akagami K; Terata K; Wakita A; Sato Y; Motoyama S; Akagami Y; Minamiya Y
J Clin Pathol; 2019 Sep; 72(9):603-608. PubMed ID: 31129615
[TBL] [Abstract][Full Text] [Related]
19. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
Solomon JP; Dell'Aquila M; Fadare O; Hasteh F
Am J Clin Pathol; 2017 Apr; 147(4):432-437. PubMed ID: 28340220
[TBL] [Abstract][Full Text] [Related]
20. High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines.
Vergara-Lluri ME; Moatamed NA; Hong E; Apple SK
Mod Pathol; 2012 Oct; 25(10):1326-32. PubMed ID: 22699517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
